• Home   /  
  • Archive by category "1"

Ventria Bioscience Case Study

commercialize Lactiva and Lysomin? The matter is made more urgent by the likely need to convince the company’s financial backers to continue to support the effort. Because of the natural cycle of agriculture-based production, missing the permitting cycle for the growing season causes the process to be delayed by a full year. 2. What groups have a stake in Ventria’s actions? Identify the relevant stakeholders and for each, state its interests and sources of power. Rice farmers and millers, environmentalists, consumer advocates, and food safety activists all appear to share a common opposition to Ventria’s proposal. The case presents evidence in the common report, Pharmaceutical Rice in California, which the latter three groups are already working closely together. A quote from farmer Joe Carrancho, which he and environmentalists “may be apart on some issues, but on this one we’re together”, suggests a possible alliance between rice farmers and environmentalists. 3. What options might emerge from a dialogue between Ventria and its relevant stakeholders? One of the themes of the textbook is that companies that actively engage with stakeholders do a better job of managing a wide range of issues than companies that do not. The process of engagement can take many forms, but it often involves dialogue with stakeholders. A dialogue occurs when a business and its stakeholders come together for face-to-face conversations about issues of common concern. There, they attempt to describe their core interests and concerns, define a common definition of the problem, invent innovative solutions for mutual gain, and establish procedures for implementing solutions. As explained in the text, to be successful, the process requires that participants express their own views fully, listen carefully and respectfully to others, and open themselves to creative thinking and new ways of looking at

BUSINESS AND THE NATURAL ENVIRONMENT 1 1. What is the problem facing Scott Deeter and Ventria? Ventria Bioscience is a venture capital-backed startup that has developed an innovative technology to produce pharmaceutical proteins in the grains of genetically engineered rice. The Sacramento-based company has conducted research, obtained patents and completed field trials of two promising products that it calls Lactiva and Lysomin. The company has built a board of directors, hired an experienced CEO (Scott Deeter), and attracted investment from angel investors and two venture capital funds. When the case opens in 2004, the next step for Ventria is to expand the production of its genetically modified rice to commercial scale. In order to do so, it needs approval by the California Secretary of Agriculture for its production protocol. Faced with significant opposition from rice farmers, environmentalists, food safety activists and foreign customers, however, the secretary has denied Ventria’s request for an “emergency” review. The problem facing Deeter at the end of the case is: How can the company best proceed to commercialize Lactiva and Lysomin? The matter is made more urgent by the likely need to convince the company’s financial backers to continue to support the effort. Because of the natural cycle of agriculture-based production, missing the permitting cycle for the growing season causes the process to be delayed by a full year. 2. What groups have a stake in Ventria’s actions? Identify the relevant stakeholders and for each, state its interests and sources of power. Stakeholder Interests Sources of Power Investors, including angel investors William Rutter and Pablo Valenzuela and venture capital funds HealthCare Ventures and Vista Ventures. The amount of their investment is not explicitly revealed in the case. However, data in the case The investors’ main interest is to earn a significant rate of return on their private investment, through an initial public offering (stock sale to the public) or through Ventria’s acquisition by a larger firm. Presumably, in The investors have very substantial power over Ventria managers, because they control the ongoing financial viability of the firm. Deeter has ongoing contact with several major investors through his

One thought on “Ventria Bioscience Case Study

Leave a comment

L'indirizzo email non verrà pubblicato. I campi obbligatori sono contrassegnati *